Jonathan Siegal Sells 4,500 Shares of Vericel (NASDAQ:VCEL) Stock

Vericel Corporation (NASDAQ:VCEL) insider Jonathan Siegal sold 4,500 shares of Vericel stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $48.90, for a total transaction of $220,050.00. Following the transaction, the insider directly owned 1,078 shares in the company, valued at $52,714.20. This trade represents a 80.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jonathan Siegal also recently made the following trade(s):

• On Friday, June 26th, Jonathan Siegal sold 2,732 shares of Vericel stock. The stock was sold at an average price of $44.90, for a total transaction of $122,666.80.

Vericel Stock Down 3.5%

Shares of Vericel stock traded down $1.65 during trading on Friday, reaching $45.96. The company’s stock had a trading volume of 521,408 shares, compared to its average volume of 606,156. Vericel Corporation has a 52-week low of $28.95 and a 52-week high of $49.32. The company has a market cap of $2.35 billion, a price-to-earnings ratio of 109.43 and a beta of 1.07. The firm’s 50-day moving average is $41.73 and its two-hundred day moving average is $37.33.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, July 30th. The biotechnology company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.08. The company had revenue of $77.46 million for the quarter, compared to analyst estimates of $72.70 million. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.01) EPS. On average, equities research analysts anticipate that Vericel Corporation will post 0.49 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VCEL. Kestra Advisory Services LLC purchased a new stake in shares of Vericel in the 4th quarter worth about $27,000. Quarry LP purchased a new stake in Vericel in the fourth quarter worth about $31,000. Farther Finance Advisors LLC lifted its holdings in Vericel by 116.5% in the fourth quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock worth $35,000 after buying an additional 522 shares during the period. Truvestments Capital LLC boosted its position in Vericel by 175.4% during the 4th quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 977 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in Vericel during the 4th quarter valued at approximately $58,000.

Trending Headlines about Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported second-quarter revenue of $77.5 million, up 22% year over year and above the $72.7 million consensus estimate. Earnings were $0.04 per share, beating expectations for a $0.04 loss, while net income reached $2.2 million and free cash flow was $14.3 million. Vericel Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $330 million-$340 million, a range that brackets or modestly exceeds the $331.9 million analyst consensus. MACI revenue growth of 23% was a key contributor to the quarterly performance. Vericel Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: The board authorized a $200 million share-repurchase program, which could support earnings per share and signal confidence in Vericel’s cash-generation outlook. Share Repurchase Program Announcement
• Positive Sentiment: Truist reaffirmed its Buy rating and increased its price target to $58 from $54. HC Wainwright also reaffirmed a Buy rating, reinforcing the favorable analyst view. Truist Financial Analyst Rating HC Wainwright Analyst Rating
• Neutral Sentiment: The earnings-call transcript and presentation provide additional operating details but do not indicate a separate material catalyst beyond the reported results and guidance. Q2 2026 Earnings Presentation
• Neutral Sentiment: Analyst sentiment is not unanimous, and Vericel trades at a high earnings multiple, leaving the shares sensitive to any slowdown in growth or weaker-than-expected future results. Conflicting Analyst Sentiment

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on VCEL shares. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Vericel in a research note on Tuesday. Weiss Ratings upgraded Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Truist Financial reaffirmed a “buy” rating and issued a $58.00 price target (up from $54.00) on shares of Vericel in a research note on Friday. TD Cowen boosted their price objective on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday. Finally, Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Vericel currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.40.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.